Oseltamivir or zanamivir

References

Citations

1. Cooper NJ, et al. (2003). Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: Systematic review and meta-analyses of randomised controlled trials. BMJ, 326(7401): 1235.

2. Treanor JT, et al. (2000). Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza. JAMA, 283(8): 1016–1024.

3. Monto AS, et al. (2002). Zanamivir prophylaxis: An effective strategy for the prevention of influenza types A and B within households. Journal of Infectious Diseases, 186(11): 1582–1588.

4. U.S. Food and Drug Administration (2006). Safety alert: Tamiflu (oseltamivir phosphate). FDA Safety Information and Adverse Event Reporting Program. Available online: http://www.fda.gov/medwatch/safety/2006/safety06.htm#tamiflu.

5. U.S. Food and Drug Administration (2008). Safety alert: Relenza (zanamivir). FDA Safety Information and Adverse Event Reporting Program. Available online: http://www.fda.gov/medwatch/safety/2008/safety08.htm#Relenza.

Author:	Maria G. Essig, MS, ELS	Last Updated: July 31, 2008
Medical Review:	Kathleen Romito, MD - Family Medicine W. David Colby IV, MSc, MD, FRCPC - Infectious Disease
© 1995-2009 Healthwise, Incorporated. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.This information does not replace the advice of a doctor. Healthwise disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. How this information was developed to help you make better health decisions.